Cancer Research UK backs Hummingbird’s cancer treatment development

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Design Cells)
(Image: Getty/Design Cells)

Related tags: Cancer research uk, Cancer, Hummingbird Bioscience, funding

Cancer Research UK to support the clinical development of Hummingbird’s investigative cancer treatment which has the potential to fight drug resistant tumours.

Hummingbird Bioscience, a biotechnology company developing cancer therapeutics, announced a partnership with Cancer Research UK charity to move its cancer treatment HMBD-001 into Phase I clinical trials.

Under the agreement, Cancer Research UK’s Centre for Drug Development will fund the program, manufacture the clinical grade antibody, and conduct the trial under the charity organization’s clinical development partnerships scheme.

HMBD-001, which was developed using Hummingbird’s rational antibody discovery platform, targets the HER3 receptor, obstructing it from binding to other cancer-associated proteins.

It is being investigated as a treatment for multiple solid tumours, including breast, gastric, pancreatic, ovarian, and lung cancers. According to Cancer Research UK, the treatment could also be effective against drug resistant cancers, as it ‘completely turns off’ the HER3 signal responsible for cancer cells’ growth.

“For many people with cancer, targeted treatments can work in the short term, but drug resistance sometimes leads to the eventual return of their tumour,” ​Nigel Blackburn, Cancer Research UK’s director of drug development, said in a statement, adding that HMBD-001 has the potential to overcome the key mechanism of drug resistance.

Following the completion of Phase I trials, Hummingbird will have the option to acquire the rights to the clinical trial results and further advance the program, otherwise Cancer Research UK will have the right to take the program forward in all indications.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more